Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Caloric Restriction Slows Age-Related Loss of Neurons by Activating SIRT1

By BiotechDaily International staff writers
Posted on 06 Jun 2013
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Caloric restriction (CR), a dietary regimen known to promote lifespan by retarding the onset of age-dependent diseases, has been found to slow the progressive loss of neurons associated with impaired cognitive capacity by activating the enzyme sirtuin 1 (SIRT1, silent mating type information regulation 2 homolog 1).

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) speculated that since aging is the greatest risk factor for neurodegeneration in the brain, CR might slow the progressive loss of neurons. To explore this possibility they used a genetically engineered mouse model that allowed for temporally and spatially controlled onset of neurodegeneration. These animals were fed a diet decreased by 30% from the normal mouse diet for three months.

Results published in the May 22, 2013, issue of the Journal of Neuroscience revealed that CR significantly delayed the onset of neurodegeneration and synaptic loss and dysfunction, and thereby preserved cognitive capacities.

“We not only observed a delay in the onset of neurodegeneration in the calorie-restricted mice, but the animals were spared the learning and memory deficits of mice that did not consume reduced-calorie diets,” said senior author Dr. Li-Huei Tsai, professor of brain and cognitive sciences at the Massachusetts Institute of Technology. “The question now is whether this type of treatment will work in other animal models, whether it is safe for use over time, and whether it only temporarily slows down the progression of neurodegeneration or stops it altogether



Channels

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.